They reported reduced phosphorylation in cerebral cortex and hippocampus and decreased levels of Alzheimer’s disease-related biomarkers after treatment with NDP-α-MSH [129]. The gene discussed is STAMBP; the disease is early-onset autosomal dominant Alzheimer disease.